抄録
Incadronate (Inc) was administered to treat hypercalcemia for five patients with advanced oral cancer. The serum calcium (Ca) level reached minimum at 5 days after the administration of 10 mg Inc, with a mean decrease of 3.4 mg/dL. In three patients Inc was repeatedly administered with a mean interval of approximately two weeks, but a decrease of Ca level was less compared with the first administration. There was no serious adverse effect in a total of 13 administrations for 5 patients. The mean survival time after the first administration was approximately one month. These results suggest the utility of Inc for controlling serum Ca level of hypercalcemia in advanced oral cancer patients, although the prognosis is very poor.
